PHASE 1/2 STUDY USING ENB-003, A FIRST-IN-CLASS SELECTIVE ETBRI, IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED REFRACTORY SOLID TUMORS

被引：1
|
作者：
Jamal, Sumayah [1 ]
Nagrial, Adnan [2 ]
Joshua, Anthony [3 ]
Eek, Richard [4 ]
Jamal, Sumayah [1 ]
机构：
[1] ENB Therapeut Inc, New York, NY USA
[2] Blacktown Canc & Haematol, Blacktown, NSW, Australia
[3] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[4] Border Med Oncol Res Unit, Albury, NSW, Australia
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0803
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
803
引用
收藏
页码：A480 / A481
页数：2
相关论文
共 50 条
  • [21] Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
    Eskens, Ferry A. L. M.
    Ramos, Francisco J.
    Burger, Herman
    O'Brien, James P.
    Piera, Adelaida
    de Jonge, Maja J. A.
    Mizui, Yoshiharu
    Wiemer, Erik A. C.
    Carreras, Maria Josepa
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6296 - 6304
  • [22] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
    Johnson, Melissa
    Dudek, Arkadiusz Z.
    Sukari, Ammar
    Call, Justin
    Kunk, Paul R.
    Lewis, Karl
    Gainor, Justin F.
    Sarantopoulos, John
    Lee, Patrice
    Golden, Adele
    Harney, Allison
    Rothenberg, S. Michael
    Zhang, Yuanyuan
    Goldman, Jonathan W.
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526
  • [23] ARTISTRY-2: a phase 1/2 study of subcutaneously administrated ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
    Powderly, John
    Carthon, Bradley
    Ernstoff, Marc
    Olszanski, Anthony
    Liu, Stephen
    Curtis, Kelly
    Du, Yangchun
    Sun, Lei
    Putiri, Emily
    Wang, Yan
    Losey, Heather
    Dezube, Bruce
    Vaishampayan, Ulka
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [24] Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors
    Lam, Elaine T.
    Eckhardt, S. Gail
    Messersmith, Wells
    Jimeno, Antonio
    O'Bryant, Cindy L.
    Ramanathan, Ramesh K.
    Weiss, Glen J.
    Chadha, Manpreet
    Oey, Abbie
    Ding, Han Ting
    Culp, Patricia A.
    Keller, Stephan F.
    Zhao, Vivian Y.
    Tsao, L. Claire
    Singhal, Anil
    Holen, Kyle D.
    Von Hoff, Daniel
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01) : 215 - 221
  • [25] A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
    Ulahannan, Susanna Varkey
    Powderly, John D.
    Johnson, Melissa Lynne
    Krauss, John C.
    Sharma, Manish
    Davar, Diwakar
    Karasic, Thomas Benjamin
    Gaillard, Stephanie
    Jenkins, Yonchu
    Stagg, Robert J.
    Bomba, Darrin
    Standifer, Nathan
    Smith, Steven
    Prasit, Peppi
    Dubensky, Thomas Walter
    Whiting, Sam H.
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] PHASE 1 STUDY OF AN ANTI-CD27 AGONIST AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Shapira-Frommer, Ronnie
    van Dongen, Marloes G. J.
    Dobrenkov, Konstantin
    Chartash, Elliot
    Liu, Fang
    Li, Claire
    Wnek, Richard
    Patel, Manish
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A2 - A2
  • [27] Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
    Xu, Jianming
    Cui, Jiuwei
    Jiang, Haiping
    Zeng, Yan
    Cong, Xiuyu
    CANCER MEDICINE, 2023, 12 (07): : 7762 - 7771
  • [28] A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors
    Hernandez Guerrero, T. C.
    Doger de Speville, B.
    Yachnin, J.
    Rohrberg, K. S.
    Borggren, M.
    Holmkvist, P.
    Karlsson, I.
    Meller, M.
    Martensson, L.
    Nilsson, J-A.
    Vaapil, M.
    Chisamore, M.
    Wallin, J. E.
    Teige, I.
    Frendeus, B.
    McAllister, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S711 - S711
  • [29] First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors
    Do, Khanh T.
    Chow, Laura Quan Man
    Reckamp, Karen
    Sanborn, Rachel E.
    Burris, Howard
    Robert, Francisco
    Camidge, D. Ross
    Steuer, Conor E.
    Strickler, John H.
    Weise, Amy
    Specht, Jennifer M.
    Gutierrez, Martin
    Haughney, Peter
    Hengel, Shawna
    Derleth, Christina Louise
    Yap, Timothy A.
    ONCOLOGIST, 2021, 26 (11): : 925 - +
  • [30] Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
    Chen, Jian Jenny
    Vincent, Melanie Y.
    Shepard, Dale
    Peereboom, David
    Mahalingam, Devalingam
    Battiste, James
    Patel, Manish R.
    Juric, Dejan
    Wen, Patrick Y.
    Bullock, Andrea
    Selfridge, Jennifer Eva
    Pant, Shubham
    Liu, Joyce
    Li, Wendy
    Fyfe, Susanne
    Wang, Suming
    Zota, Victor
    Mahoney, James
    Watnick, Randolph S.
    Cieslewicz, Michael
    Watnick, Jing
    COMMUNICATIONS MEDICINE, 2024, 4 (01):
12345